Osang Healthcare (OHC), which recently signed a comprehensive business cooperation agreement with Yuhan Corp., has emerged as the second largest shareholder of one of the latter’s subsidiaries.Osang Healthcare said Thursday that the company has completed paying money for the three-party capital incr
The recent mislabeling of medicines by Hyundai Pharm and other incidents of drug mix-ups are threatening consumers’ health, consumer groups said.Issuing a statement Wednesday, the Citizens United for Consumer Sovereignty (CUCS), a consumer advocacy group, criticized Hyundai Pharm’s labeling errors,
Astellas Korea has officially launched Padcev (ingredient: enfortumab vedotin), which treats locally advanced or metastatic urothelial cancer.Padcev, an antibody-drug conjugate (ADC) that targets Nectin-4, received approval from the Ministry of Drug Safety as a monotherapy in March. It has a categor
Pfizer's first-in-class CDK4/6 inhibitor, Ibrance (palbociclib), has received an expanded indication in Korea.It can now be used as first-line endocrine therapy in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast
GC Biopharma said on Wednesday that its quadrivalent flu vaccine, GC FLU Quadrivalent inj., has been approved by the Egyptian Drug Authority (EDA), marking the company's first approval on the African continent. Egypt has one of the largest pharmaceutical markets in the African region, with the flu v
Multinational pharmaceutical companies are partnering with government agencies or pharmaceutical industry associations to bolster innovation in the Korean biotech sector.These support programs aim to bridge the gap between research and market access, providing essential resources, mentorship, and fu
In the ever-evolving landscape of pharmaceutical logistics, Marken aims to become a trailblazer, offering logistic services tailored exclusively to the biopharma industry.To get more in-depth knowledge about the sector, Korea Biomedical Review recently met with Mary Ahn, Country Manager of Marken Ko
Prestige BioPharma, a Singapore-based pharmaceutical company specializing in antibody biopharmaceuticals, said on Tuesday that it joined the Cancer Moonshot Project promoted by U.S. President Joe Biden. This is the first time a Kospi-listed company and antibody drug developer has joined the Cancer M
HLB said the U.S. Food and Drug Administration (FDA) has initiated a review for approving a combination therapy of rivoceranib and camrelizumab as the first-line treatment for hepatocellular carcinoma (HCC).The company filed a new drug application (NDA) in May.HLB Group Chairman Jin Yang-gon said on
GI Innovation expressed its intention to pursue a license out deal for GI-301, an allergy treatment, with Japanese companies at a press conference at the Grand InterContinental Seoul Parnas Hotel, in southern Seoul, on Monday. "We are currently in talks with three Japanese pharmaceutical companies t
Boehringer Ingelheim has launched Esgliteo (empagliflozin/linagliptin), a compound therapy of the SGLT-2 inhibitor Jardiance (empagliflozin) and the DPP-4 inhibitor Trajenta (linagliptin), with insurance coverage in Korea.Boehringer Ingelheim on Monday announced the domestic launch of Esgliteo (empa
GC said it has submitted a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) for Alyglo, its 10 percent intravenous immunoglobulin.Alyglo, sold under the brand name IVIG-SN 10 percent in Korea, is a liquid immunoglobulin preparation purified from plasma fractions.Kor
Amid a protracted labor conflict at MSD Korea due to the company’s decision to abolish its general medicine (GM) division, the management has expanded the eligibility for its early retirement program (ERP) while increasing compensation money.MSD Korea recently announced the expansion of the ERP to a
"We must keep the hard-won flame alive. It is imperative to increase the self-reliance in active pharmaceutical ingredients (API) to establish pharmaceutical sovereignty by improving the self-sufficiency rate of medicines."Han Ssang-soo, who chairs the Special Committee for API within the Korea Phar
Handok recalls part of the domestic supply of its antiepileptic treatment, Sabril Tab 500mg (vigabatrin), likely exacerbating the drug’s supply shortage.According to the Ministry of Food and Drug Safety (MFDS), Handok has recalled some batches of Sabril 500 mg (manufacturing number SAFA001) since la
Experts from U.S. venture capitals (VCs) cited overvaluation, lack of access, and management issues as reasons for not investing in Korean pharmaceutical companies on the last day of Bioplus-Interphex in Seoul.The most common issue highlighted by all panelists was the inflated valuation of assets of
Making all out efforts to become a leader in the microbiome business, Korea officially launched the Microbiome New Drug Business Council on Thursday to help establish Korea’s competitiveness in the global market.The council's launch is expected to promote various projects, such as building a global
A first-in-class cold agglutin disease treatment that won approval based on clinically confirmed efficacy and safety has arrived in Korea.On Wednesday, the Ministry of Food and Drug Safety said it approved Sanofi’s Enjaymo (sutimlimab) to treat hemolysis in adult patients with cold agglutinin diseas
Amid a global decline in the bioindustry over the past two years, Korea ranked third in Asia in Cytiva’s pharmaceutical and biotech recovery index, the globa life sciences company said.Korea’s resilience in bio resulted from strong government policies and regulations but the nation lacked investment
Hanmi Pharm received a two-month administrative suspension from selling Eyeporin Eye Drops for failing to submit drug equivalencye test data on July 6, according to the Ministry of Food and Drug Safety.The treatment is used for ocular inflammation associated with dry keratoconjunctivitis.Accordingly